Sector — Life Sciences & Healthcare
AI Advisory for Life Sciences & Healthcare
Life sciences AI carries some of the most complex compliance obligations in the EU AI Act. Getting classification right matters.
The regulatory complexity facing life sciences AI
Irish life sciences and healthcare organisations operate in one of the most regulated AI environments in the EU. Medical AI that falls under the MDR or IVDR is automatically classified as high-risk under the EU AI Act — triggering conformity assessment, registration, and human oversight requirements on top of existing regulatory obligations. Meanwhile, non-clinical AI (commercial analytics, HR tools, operational systems) is subject to standard deployer obligations. Understanding which framework applies to which system is the starting point for any compliance programme.
Key challenges for life sciences organisations
- High-risk AI classification under EU AI Act for diagnostic and clinical tools
- Regulatory overlap: EU AI Act, MDR, GDPR and HTA obligations
- AI governance frameworks for clinical and non-clinical AI use
- Vendor assessment for AI tools used in clinical pathways
- Board and leadership oversight of AI risk in patient-facing systems
Copilot and AI productivity in life sciences
Beyond clinical AI, Irish life sciences organisations have invested heavily in Microsoft Copilot and productivity AI. The challenge is the same as in other sectors: licences purchased but measurable productivity gains not realised. A recent life sciences engagement diagnosed the gap between Copilot investment and actual productivity impact — identifying the specific workflows where adoption was creating value and those where it was generating noise. The output was a structured adoption plan with measurable milestones, not a generic Copilot rollout guide.
Common questions
Is medical AI classified as high-risk under the EU AI Act?
AI systems intended for medical purposes that are subject to the EU Medical Device Regulation (MDR) or In Vitro Diagnostic Regulation (IVDR) are automatically classified as high-risk under the EU AI Act. This includes AI used in diagnostic imaging, clinical decision support, patient monitoring and treatment planning. For these systems, the EU AI Act's most demanding obligations apply: technical documentation, conformity assessment, registration in the EU AI Act database, and human oversight requirements. Life sciences organisations using or deploying such systems need a clear classification exercise and compliance roadmap.
How does the EU AI Act interact with existing healthcare regulation in Ireland?
The EU AI Act adds a compliance layer on top of existing healthcare regulation — it does not replace GDPR, MDR, IVDR, or HIQA standards. In practice, a life sciences or healthcare organisation must satisfy all applicable frameworks simultaneously. The good news is that organisations that have already built compliance infrastructure for MDR or IVDR will have significant foundations to build from. The EU AI Act adds documentation, oversight, and registration requirements on top of what already exists — but it doesn't require starting from scratch. A readiness review maps the overlap and identifies the genuine gaps.
What AI governance does a pharmaceutical company need?
A pharmaceutical company using AI needs governance that covers both patient-facing AI (where EU AI Act high-risk obligations may apply) and operational AI (research tools, manufacturing optimisation, commercial analytics). The governance framework needs to distinguish between these categories, assign accountability for each system, and establish oversight mechanisms appropriate to the risk level. It also needs to be built for the regulatory environment in which the company operates — including GxP requirements where applicable. Our advisory is vendor-neutral: we work with your existing systems and obligations, not around a platform we want to sell you.
Book an AI Readiness Review
Vendor-neutral. Fixed-fee. Designed for regulated environments.